Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc. reports developments as a pharmaceutical company with commercial generic prescription drugs in Canada and proprietary drug-development programs in oncology and antivirals. News commonly covers product launches through its Nora Pharma subsidiary, including generic medicines such as Domperidone, Doxycycline and Pravastatin, as well as Health Canada commercialization approvals and expansion of therapeutic categories.
The company’s updates also address financial results, portfolio growth and research programs including K1.1 mRNA, an mRNA-lipid nanoparticle candidate targeting liver cancer, and a PLpro protease inhibitor for SARS-related coronavirus infections. Corporate and treasury actions may appear alongside operating updates when they affect Sunshine Biopharma’s capital strategy or public-company profile.
Sunshine Biopharma (SBFM) has filed a nonprovisional PCT patent application for its COVID-19 treatment, enhancing its intellectual property rights. This builds on a provisional application from May 2020, now extending coverage to include the Papain-Like Coronavirus protease (PLpro), crucial for viral replication and immune suppression. Collaborating with the University of Georgia, Sunshine is evaluating two PLpro inhibitors in hACE2-transgenic mice, aiming for efficacy against COVID-19 variants. The company also continues developing Adva-27a, an anticancer drug effective against multidrug-resistant cancers.
Sunshine Biopharma (SBFM) announced an additional $500,000 investment from RB Capital to support its Coronavirus drug development program. This funding will also facilitate research on the anti-cancer drug Adva-27a. The company is advancing its COVID-19 treatment, SBFM-PL4, alongside two compounds licensed from the University of Georgia, with promising initial results seen in mice studies. Sunshine Biopharma aims to expedite the drug development process and potentially seek FDA authorization for human trials.
Sunshine Biopharma (SBFM) has successfully completed a Maximum Tolerated Dose (MTD) study in mice for its COVID-19 treatment, demonstrating favorable results within the optimum range for human use. This antiviral drug, targeting PLpro, aims to inhibit SARS-CoV-2 replication. Following these results, Sunshine Biopharma plans to conduct efficacy studies in hACE2-transgenic mice. Additionally, they are developing an anticancer compound, Adva-27a, which has shown effectiveness against multidrug-resistant cancer cells, with clinical trials planned at McGill University.
Sunshine Biopharma (SBFM) has secured $2,054,000 in financing, exceeding the initially announced $2,000,000 from RB Capital Partners. This funding, convertible at $0.43 per share, will support the development of its Coronavirus treatment and the anticancer drug Adva-27a, targeting pancreatic cancer. The company is conducting studies in collaboration with the University of Georgia to assess the efficacy of its antiviral compounds in transgenic mice. Clinical trials for Adva-27a are planned at McGill University’s Jewish General Hospital.
Sunshine Biopharma (SBFM) announced a 'Notice of Allowance' from the European Patent Office for a new patent on its anticancer compound, Adva-27a, extending its European protection until 2033. This follows a similar patent granted in the U.S. in 2019. Sunshine Biopharma is the sole owner of Adva-27a's intellectual property. The compound shows promising results against multidrug-resistant cancers, with upcoming clinical trials planned at McGill University. The company is also developing antiviral treatments for COVID-19, aiming to advance multiple compounds for clinical testing.
Sunshine Biopharma (SBFM) has announced the shipment of a new batch of Adva-27a from China to its laboratories in Montreal. Following quality assurance testing, the company will conduct tumor inhibition studies on xenograft mice with human pancreatic cancer. Adva-27a has shown promise in preclinical trials against various cancer types, including pancreatic cancer, known for its resistance to chemotherapy. Clinical trials are planned at McGill University’s Jewish General Hospital. The company also continues development on COVID-19 treatments.
Sunshine Biopharma (OTC PINK: SBFM) announced the launch of its new eCommerce website, Nutrition.SunshineBiopharma.com, featuring over 20 nutritional products, including amino acids and vitamins. The site supports customers in browsing and ordering supplements conveniently. Essential 9™, one of the featured products, contains all nine essential amino acids crucial for protein synthesis and immune support. With eCommerce sales projected to grow from $374 billion in 2020 to $476 billion by 2024, Sunshine aims to enhance its market presence while maintaining strict manufacturing standards.
Sunshine Biopharma (SBFM) has launched its new eCommerce website, Nutrition.SunshineBiopharma.com, featuring over 20 nutritional products, including Essential 9™, designed to support optimal health. The website aims to enhance the shopping experience for consumers seeking high-quality nutritional supplements, available 24/7. With eCommerce sales projected to rise from $374 billion in 2020 to $476 billion by 2024, the launch positions SBFM to capitalize on the growing market.
Sunshine Biopharma (OTC PINK:SBFM) announced the start of a critical transgenic mice study for its COVID-19 treatment, aimed at inhibiting virus replication via protease inhibitors. The study, conducted at the University of Georgia, uses genetically modified mice susceptible to SARS-CoV-2. Success in these studies may lead to FDA submissions for human trials. Sunshine Biopharma's COVID-19 treatment has seen progress since its provisional patent filing in May 2020, with a lead compound identified as SBFM-PL4.
Sunshine Biopharma (OTC PINK:SBFM) announced an exclusive license agreement with the University of Georgia for two patented Anti-Coronavirus compounds. This partnership aims to advance the compounds' development alongside SBFM-PL4, Sunshine's lead Anti-Coronavirus compound. The efficacy testing will involve genetically modified mice susceptible to SARS-CoV-2, with trials expected to commence this month. Furthermore, Sunshine is actively developing Adva-27a, an anticancer drug targeting multidrug-resistant cancer cells and planning clinical trials for pancreatic cancer.